Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according to a new report from Research and Markets, sales could swell to $104.9 billion by 2035.Novo Nordisk (NYSE: NVO) markets the top-selling GLP-1 drug at the moment, but it has been losing market share to tirzepatide, a drug that Eli Lilly (NYSE: LLY) started marketing for weight management in 2023 under the brand name Zepbound.Sales of Zepbound, administered via a weekly injection, are soaring, but a potential competitor from Viking Therapeutics (NASDAQ: VKTX) has been gaining a lot of attention. Mid-stage clinical trial data suggests Viking's candidate could outperform Lilly's blockbuster and become a new top-selling anti-obesity drug.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool